Clinical characteristics and prognostic analysis of primary malignant bone lymphoma

Jing Zhao, Huaqing Wang, Zhengzi Qian, Huilai Zhang, Lihua Qiu, Shiyong Zhou, Lanfang Li, Kai Fu

Research output: Contribution to journalArticle

Abstract

Objective: To investigate the clinical features and prognostic factors of primary bone lymphoma (PBL). Methods: A retrospective analysis was performed based on the clinical records of 37 PBL cases treated at the Tianjin Medical University Cancer Hospital between June 1995 and May 2009. Survival curves were plotted using the Kaplan-Meier method, with the Log-rank COX regression model to evaluate the independent prognostic factors. Results: The median age of patients was 61 years (range 18-85 years). Ostealgia was the initial symptom. The majority of cases presented with diffuse large B-cell non-Hodgkin's lymphoma. Through chemotherapy and/or radiotherapy, 18 patients achieved complete remission (CR) and 13 achieved partial remission (PR), with a median follow-up of 32 months (7-171 months). The 5- and 10-year overall survival rates were 59.5% and 43.2%, respectively. The patients treated with chemotherapy ≥4 cycles combined with rituximab for B cell lymphoma achieved better outcomes. In the multivariate analysis, the Ann Arbor stage, B symptoms, ages, and the number of extranodal involvement sites were independent prognostic factors. Conclusion: Primary bone non-Hodgkin's lymphoma should be treated with a multi-modality strategy. Treatment with more than 4 cycles of doxorubicin-based chemotherapy after orchiectomy is recommended. For B cell lymphoma, rituximab plus chemotherapy is preferred. Pamidronate disodium is necessary. The Ann Arbor stage, B symptom, age, and number of extranodal sites are independent prognostic factors of PBL.

Original languageEnglish (US)
Pages (from-to)1118-1119+1123
JournalChinese Journal of Clinical Oncology
Volume38
Issue number18
DOIs
StatePublished - Sep 30 2011

Fingerprint

Lymphoma
B-Cell Lymphoma
Bone and Bones
Drug Therapy
pamidronate
Non-Hodgkin's Lymphoma
Cancer Care Facilities
Orchiectomy
Doxorubicin
Radiotherapy
Multivariate Analysis
Survival Rate
Survival
Rituximab
Therapeutics

Keywords

  • Clinical features
  • Primary bone lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Clinical characteristics and prognostic analysis of primary malignant bone lymphoma. / Zhao, Jing; Wang, Huaqing; Qian, Zhengzi; Zhang, Huilai; Qiu, Lihua; Zhou, Shiyong; Li, Lanfang; Fu, Kai.

In: Chinese Journal of Clinical Oncology, Vol. 38, No. 18, 30.09.2011, p. 1118-1119+1123.

Research output: Contribution to journalArticle

Zhao, Jing ; Wang, Huaqing ; Qian, Zhengzi ; Zhang, Huilai ; Qiu, Lihua ; Zhou, Shiyong ; Li, Lanfang ; Fu, Kai. / Clinical characteristics and prognostic analysis of primary malignant bone lymphoma. In: Chinese Journal of Clinical Oncology. 2011 ; Vol. 38, No. 18. pp. 1118-1119+1123.
@article{5e25595fec3e4433b9522e987bff000b,
title = "Clinical characteristics and prognostic analysis of primary malignant bone lymphoma",
abstract = "Objective: To investigate the clinical features and prognostic factors of primary bone lymphoma (PBL). Methods: A retrospective analysis was performed based on the clinical records of 37 PBL cases treated at the Tianjin Medical University Cancer Hospital between June 1995 and May 2009. Survival curves were plotted using the Kaplan-Meier method, with the Log-rank COX regression model to evaluate the independent prognostic factors. Results: The median age of patients was 61 years (range 18-85 years). Ostealgia was the initial symptom. The majority of cases presented with diffuse large B-cell non-Hodgkin's lymphoma. Through chemotherapy and/or radiotherapy, 18 patients achieved complete remission (CR) and 13 achieved partial remission (PR), with a median follow-up of 32 months (7-171 months). The 5- and 10-year overall survival rates were 59.5{\%} and 43.2{\%}, respectively. The patients treated with chemotherapy ≥4 cycles combined with rituximab for B cell lymphoma achieved better outcomes. In the multivariate analysis, the Ann Arbor stage, B symptoms, ages, and the number of extranodal involvement sites were independent prognostic factors. Conclusion: Primary bone non-Hodgkin's lymphoma should be treated with a multi-modality strategy. Treatment with more than 4 cycles of doxorubicin-based chemotherapy after orchiectomy is recommended. For B cell lymphoma, rituximab plus chemotherapy is preferred. Pamidronate disodium is necessary. The Ann Arbor stage, B symptom, age, and number of extranodal sites are independent prognostic factors of PBL.",
keywords = "Clinical features, Primary bone lymphoma, Prognosis",
author = "Jing Zhao and Huaqing Wang and Zhengzi Qian and Huilai Zhang and Lihua Qiu and Shiyong Zhou and Lanfang Li and Kai Fu",
year = "2011",
month = "9",
day = "30",
doi = "10.3969/j.issn.1000-8179.2011.18.016",
language = "English (US)",
volume = "38",
pages = "1118--1119+1123",
journal = "Chinese Journal of Clinical Oncology",
issn = "1672-7118",
publisher = "China Anti-Cancer Association",
number = "18",

}

TY - JOUR

T1 - Clinical characteristics and prognostic analysis of primary malignant bone lymphoma

AU - Zhao, Jing

AU - Wang, Huaqing

AU - Qian, Zhengzi

AU - Zhang, Huilai

AU - Qiu, Lihua

AU - Zhou, Shiyong

AU - Li, Lanfang

AU - Fu, Kai

PY - 2011/9/30

Y1 - 2011/9/30

N2 - Objective: To investigate the clinical features and prognostic factors of primary bone lymphoma (PBL). Methods: A retrospective analysis was performed based on the clinical records of 37 PBL cases treated at the Tianjin Medical University Cancer Hospital between June 1995 and May 2009. Survival curves were plotted using the Kaplan-Meier method, with the Log-rank COX regression model to evaluate the independent prognostic factors. Results: The median age of patients was 61 years (range 18-85 years). Ostealgia was the initial symptom. The majority of cases presented with diffuse large B-cell non-Hodgkin's lymphoma. Through chemotherapy and/or radiotherapy, 18 patients achieved complete remission (CR) and 13 achieved partial remission (PR), with a median follow-up of 32 months (7-171 months). The 5- and 10-year overall survival rates were 59.5% and 43.2%, respectively. The patients treated with chemotherapy ≥4 cycles combined with rituximab for B cell lymphoma achieved better outcomes. In the multivariate analysis, the Ann Arbor stage, B symptoms, ages, and the number of extranodal involvement sites were independent prognostic factors. Conclusion: Primary bone non-Hodgkin's lymphoma should be treated with a multi-modality strategy. Treatment with more than 4 cycles of doxorubicin-based chemotherapy after orchiectomy is recommended. For B cell lymphoma, rituximab plus chemotherapy is preferred. Pamidronate disodium is necessary. The Ann Arbor stage, B symptom, age, and number of extranodal sites are independent prognostic factors of PBL.

AB - Objective: To investigate the clinical features and prognostic factors of primary bone lymphoma (PBL). Methods: A retrospective analysis was performed based on the clinical records of 37 PBL cases treated at the Tianjin Medical University Cancer Hospital between June 1995 and May 2009. Survival curves were plotted using the Kaplan-Meier method, with the Log-rank COX regression model to evaluate the independent prognostic factors. Results: The median age of patients was 61 years (range 18-85 years). Ostealgia was the initial symptom. The majority of cases presented with diffuse large B-cell non-Hodgkin's lymphoma. Through chemotherapy and/or radiotherapy, 18 patients achieved complete remission (CR) and 13 achieved partial remission (PR), with a median follow-up of 32 months (7-171 months). The 5- and 10-year overall survival rates were 59.5% and 43.2%, respectively. The patients treated with chemotherapy ≥4 cycles combined with rituximab for B cell lymphoma achieved better outcomes. In the multivariate analysis, the Ann Arbor stage, B symptoms, ages, and the number of extranodal involvement sites were independent prognostic factors. Conclusion: Primary bone non-Hodgkin's lymphoma should be treated with a multi-modality strategy. Treatment with more than 4 cycles of doxorubicin-based chemotherapy after orchiectomy is recommended. For B cell lymphoma, rituximab plus chemotherapy is preferred. Pamidronate disodium is necessary. The Ann Arbor stage, B symptom, age, and number of extranodal sites are independent prognostic factors of PBL.

KW - Clinical features

KW - Primary bone lymphoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=80855141691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80855141691&partnerID=8YFLogxK

U2 - 10.3969/j.issn.1000-8179.2011.18.016

DO - 10.3969/j.issn.1000-8179.2011.18.016

M3 - Article

AN - SCOPUS:80855141691

VL - 38

SP - 1118-1119+1123

JO - Chinese Journal of Clinical Oncology

JF - Chinese Journal of Clinical Oncology

SN - 1672-7118

IS - 18

ER -